Jason Xynellis, PA
Medical · Providence, RINPI 1952501942
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,752 of the $7,386 with a category attached, or 64.3%. 27 manufacturers reported payments, led by AbbVie at 58.1% of the total. Among medical clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $28.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$612
- Exact Sciences$548
- Pfizer$376
- Phathom Pharmaceuticals, Inc.$369
- Johnson & Johnson$310
- plus $876 from 21 others
What the payments were for
- Consulting fees$2,62536%
- Food & beverage$4,75264%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $4,295 |
| Novo Nordisk | 34 | $612 |
| Exact Sciences | 19 | $548 |
| Pfizer | 30 | $376 |
| Phathom Pharmaceuticals, Inc. | 17 | $369 |
| Johnson & Johnson | 27 | $310 |
| Lilly USA, LLC | 9 | $176 |
| Nestle Healthcare Nutrition Inc. | 5 | $106 |
| AstraZeneca | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| GSK | 2 | $50 |
| Amgen | 2 | $48 |
| Shield Therapeutics Inc | 3 | $44 |
| Bayer | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Merck | 2 | $28 |
| Tolmar, Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Gilead | 1 | $22 |
| Abbott | 1 | $22 |
| Covis Pharma GmbH | 1 | $21 |
| Lundbeck LLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,386 in reported general payments places this provider in the 90th percentile of 77 medical providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $32,147 |
| MounjaroTirzepatide | 12 | $12,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,522 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,719 |
| OxycontinOxycodone Hcl | 14 | $7,678 |
| Buprenorphine | 25 | $6,526 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,075 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,316 |
| Rivastigmine | 26 | $4,322 |
| Gabapentin | 89 | $2,076 |
| Tramadol Hcl ErTramadol Hcl | 15 | $1,487 |
| Omeprazole | 69 | $1,417 |
| Atorvastatin Calcium | 170 | $1,310 |
| Losartan Potassium | 121 | $1,170 |
| Duloxetine Hcl | 45 | $1,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $376 | $32,14751 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $50 | $20,24237 claims |
| Lilly USA, LLCMounjaro | $176 | $12,32212 claims |
| Boehringer IngelheimCombivent Respimat | $14 | $6,07512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $5,31611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 medical providers in Rhode Island.
Other medical in Providence
- Amanda MattesonProvidence$8K
- Ian KrousonProvidence$5K
- Ernest SilvaProvidence$3K
- Joseph DesrosiersProvidence$2K
- Kailey WellsProvidence$2K
- Daniel PiascikProvidence$2K
- Sonia PeckProvidence$2K
- Phathsady LouangxayProvidence$1K
- Shauna SnitkoProvidence$835
- Kenneth FurcoloProvidence$511
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.